Mesoblast Lists On Nasdaq
November 15, 2015 18:46 ET
|
Mesoblast
MELBOURNE, Australia and NEW YORK, Nov. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (NASDAQ:MESO) today announced it had listed on the Nasdaq Global Market on 13 November under the symbol...
Mesoblast Announces Pricing Of Public Offering On Nasdaq
November 13, 2015 08:38 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO) (ASX:MSB), a world leader in the development of innovative cell-based medicines, today announced...
Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions
October 27, 2015 21:07 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Oct. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Patent and Trademark Office (USPTO) has granted a...
Mesoblast Chairman's Address to 2015 Annual General Meeting
October 22, 2015 02:00 ET
|
Mesoblast
NEW YORK, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Thank you for attending the Mesoblast 2015 Annual General Meeting.
This has been another exciting and productive year in the history of our...
Celgene and Mesoblast Extend Agreement
October 15, 2015 19:49 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that it has agreed with Celgene Corporation to extend for a period of...
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
September 29, 2015 21:10 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for...
Full Product Approval In Japan Received By Mesoblast Licensee
September 18, 2015 01:23 ET
|
Mesoblast
NEW YORK CITY and MELBOURNE, Australia, Sept. 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full...
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
September 03, 2015 20:44 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine...
Mesoblast Reports 2015 Financial Year Results And Provides Update On Phase 3 Chronic Heart Failure Program
August 16, 2015 20:28 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 16, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported its 2015 full financial year results, and provided an update on important...
Type 2 Diabetes Trial Results Published In Diabetes Care
July 22, 2015 19:17 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, July 22, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results of the Phase 2 trial of its intravenously-delivered...